The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …

Purpose The newly emerged coronavirus (SARS-CoV-2) continues to infect humans, and no
completely efficient treatment has yet been found. Antibody therapy is one way to control …

The number of applications for nanobodies is steadily expanding, positioning these
molecules as fast-growing biologic products in the biotechnology market. Several of their …

Heterogeneous antigen expression is a key barrier influencing the activity of chimeric
antigen receptor (CAR) T cells in solid tumors. Here, we develop CAR T cells targeting …

There is growing interest in identifying antibodies that protect against infectious diseases,
especially for high-risk individuals and pathogens for which no vaccine is yet available …

Over the years, infectious diseases with high morbidity and mortality disrupted human
healthcare systems and devastated economies globally. Respiratory viruses, especially …

Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) initially emerged in December 2019 and has subsequently expanded …

The interaction between the Spike (S) protein of SARS-CoV-2 and the human angiotensin
converting enzyme 2 (hACE2) is essential for infection, and is a target for neutralizing …

新冠肺炎的大暴发再次引起了人们对于病毒感染性疾病的关注, 研发抗病毒药物对于已知的和
可能新出现的病毒都具有重要意义. 近年来, 多肽和蛋白质类药物正成为抗病毒药物研发领域的 …

Introduction The ongoing COVID-19 pandemic situation caused by SARS-CoV-2 and
variants of concern such as B. 1.617. 2 (Delta) and recently, B. 1.1. 529 (Omicron) is posing …